Teva Pharmaceutical Industries Share Price (NYSE: TEVA)

$18.21

▲

0.35

(1.96%)

Live

Last updated on August 19, 2025 at 12:37 AM IST

$₹

Check the interactive Teva Pharmaceutical Industries Stock chart to analyse performance

Teva Pharmaceutical Industries stock performance

as on August 19, 2025 at 12:37 AM IST

Today's Low:$18.01
Today's High:$18.26
$18.21
1.1%
Downside
Day's Volatility :1.37%
Upside
0.27%
52 Weeks Low:$12.47
52 Weeks High:$22.80
$18.21
31.55%
Downside
52 Weeks Volatility :45.33%
Upside
20.13%

Teva Pharmaceutical Industries Stock Returns

Period	Teva Pharmaceutical Industries Ltd	Sector (Health Care)	Index (Russel 2000)
3 Months	4.94%	2.3%	0.0%
6 Months	7.79%	-5.8%	0.0%
1 Year	-2.35%	-10.9%	0.0%
3 Years	72.23%	2.8%	-11.6%

Teva Pharmaceutical Industries Ltd Key Stats

Check Teva Pharmaceutical Industries key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.86
Open	$17.695
Today's High	$18.26
Today's Low	$18.01
Market Capitalization	$20.5B
Today's Volume	$8.3M
52 Week High	$22.8
52 Week Low	$12.465
Revenue TTM	$16.6B
EBITDA	$4.5B
Earnings Per Share (EPS)	$-0.15
Profit Margin	-0.94%
Quarterly Earnings Growth YOY	0.4%
Return On Equity TTM	-2.42%

Stock Returns calculator for Teva Pharmaceutical Industries Stock including INR - Dollar returns

The Teva Pharmaceutical Industries stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Teva Pharmaceutical Industries investment value today

Current value as on today

₹1,03,636

Returns

₹3,636

(+3.64%)

Returns from Teva Pharmaceutical Industries Stock

₹437 (-0.44%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Teva Pharmaceutical Industries Stock

17%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Teva Pharmaceutical Industries Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Teva Pharmaceutical Industries Ltd

Name
Holdings %
Name
Holdings %
FMR Inc
7.21%
BlackRock Inc
4.55%
Ion Asset Management Ltd.
3.40%
Clal Insurance Enterprises Holdings Ltd
3.29%
MENORA MIVTACHIM HOLDINGS LIMITED
2.54%
Exor Investments (UK) LLP
2.43%

Analyst Recommendation on Teva Pharmaceutical Industries Stock

Rating

Trend

Sell

0%Buy

33%Hold

66%Sell

Based on 9 Wall street analysts offering stock ratings for Teva Pharmaceutical Industries(by analysts ranked 0 to 5 stars)

Teva Pharmaceutical Industries Share Price Target

What analysts predicted

Upside of 29.36%

Target:

$23.56

Current:

$18.21

Teva Pharmaceutical Industries share price target is $23.56, a slight Upside of 29.36% compared to current price of $18.21 as per analysts' prediction.

Teva Pharmaceutical Industries Stock Insights

Price Movement
In the last 7 days, TEVA stock has moved up by 8.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 3.89B → 4.17B (in $), with an average increase of 6.8% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -845.0M → 282.0M (in $), with an average increase of 105.1% per quarter
TEVA vs HLN (1 yr)
In the last 1 year, Teva Pharmaceutical Industries Ltd has experienced a drawdown of -2.2%, however Haleon Plc Spon Ads resisted the overall trend and outperformed by 1.9%
Price to Sales
ForTEVA every $1 of sales, investors are willing to pay $1.2, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

Teva Pharmaceutical Industries Ltd Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$16.9B	↓ 10.43%
Net Income	$-999.0M	↓ 53.53%
Net Profit Margin	-5.92%	↑ 5.48%

	FY20	Y/Y Change
Revenue	$16.7B	↓ 1.36%
Net Income	$-4.0B	↑ 299.4%
Net Profit Margin	-23.95%	↓ 18.03%

	FY21	Y/Y Change
Revenue	$15.9B	↓ 4.68%
Net Income	$417.0M	↓ 110.45%
Net Profit Margin	2.63%	↑ 26.58%

	FY22	Y/Y Change
Revenue	$14.9B	↓ 6.0%
Net Income	$-2.4B	↓ 664.27%
Net Profit Margin	-15.77%	↓ 18.4%

	FY23	Y/Y Change
Revenue	$15.8B	↑ 6.17%
Net Income	$-559.0M	↓ 76.24%
Net Profit Margin	-3.53%	↑ 12.24%

	FY24	Y/Y Change
Revenue	$16.5B	↑ 4.4%
Net Income	$-1.6B	↑ 193.2%
Net Profit Margin	-9.91%	↓ 6.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.8B	↓ 14.02%
Net Income	$-139.0M	↓ 132.4%
Net Profit Margin	-3.63%	↓ 13.26%

	Q2 FY24	Q/Q Change
Revenue	$4.2B	↑ 8.61%
Net Income	$-845.0M	↑ 507.91%
Net Profit Margin	-20.3%	↓ 16.67%

	Q3 FY24	Q/Q Change
Revenue	$4.3B	↑ 4.08%
Net Income	$-437.0M	↓ 48.28%
Net Profit Margin	-10.09%	↑ 10.21%

	Q4 FY24	Q/Q Change
Revenue	$4.2B	↓ 2.38%
Net Income	$-217.0M	↓ 50.34%
Net Profit Margin	-5.13%	↑ 4.96%

	Q1 FY25	Q/Q Change
Revenue	$3.9B	↓ 7.99%
Net Income	$214.0M	↓ 198.62%
Net Profit Margin	5.5%	↑ 10.63%

	Q2 FY25	Q/Q Change
Revenue	$4.2B	↑ 7.32%
Net Income	$282.0M	↑ 31.78%
Net Profit Margin	6.75%	↑ 1.25%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$7.5B	↓ 9.16%

	FY20	Y/Y Change
Profit	$7.7B	↑ 2.51%

	FY21	Y/Y Change
Profit	$7.6B	↓ 1.7%

	FY22	Y/Y Change
Profit	$7.0B	↓ 8.18%

	FY23	Y/Y Change
Profit	$7.6B	↑ 9.64%

	FY24	Y/Y Change
Profit	$8.1B	↑ 5.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.8B	↓ 26.16%

	Q2 FY24	Q/Q Change
Profit	$2.0B	↑ 13.34%

	Q3 FY24	Q/Q Change
Profit	$2.1B	↑ 6.23%

	Q4 FY24	Q/Q Change
Profit	$2.1B	↓ 1.3%

	Q1 FY25	Q/Q Change
Profit	$1.9B	↓ 11.46%

	Q2 FY25	Q/Q Change
Profit	$2.1B	↑ 11.99%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$538.0M	↓ 78.0%
Investing Cash Flow	$1.4B	↓ 27.38%
Financing Cash Flow	$-241.0M	↓ 92.81%

	FY20	Y/Y Change
Operating Cash Flow	$1.2B	↑ 126.02%
Investing Cash Flow	$863.0M	↓ 36.31%
Financing Cash Flow	$-1.9B	↑ 682.16%

	FY21	Y/Y Change
Operating Cash Flow	$798.0M	↓ 34.37%
Investing Cash Flow	$1.5B	↑ 76.48%
Financing Cash Flow	$-2.2B	↑ 15.23%

	FY22	Y/Y Change
Operating Cash Flow	$1.6B	↑ 99.25%
Investing Cash Flow	$656.0M	↓ 56.93%
Financing Cash Flow	$-1.5B	↓ 31.54%

	FY23	Y/Y Change
Operating Cash Flow	$1.4B	↓ 13.96%
Investing Cash Flow	$968.0M	↑ 47.56%
Financing Cash Flow	$-1.9B	↑ 28.65%

	FY24	Y/Y Change
Operating Cash Flow	$1.2B	↓ 8.85%
Investing Cash Flow	$792.0M	↓ 18.18%
Financing Cash Flow	$-1.8B	↓ 6.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$171.0M	↓ 85.56%
Investing Cash Flow	$-215.0M	↓ 171.43%
Financing Cash Flow	$-87.0M	↓ 84.9%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$420.0M	↑ 145.61%
Investing Cash Flow	$-139.0M	↓ 35.35%
Financing Cash Flow	$-966.0M	↑ 1010.34%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$693.0M	↑ 65.0%
Investing Cash Flow	$268.0M	↓ 292.81%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$575.0M	↓ 17.03%
Investing Cash Flow	$202.0M	↓ 24.63%
Financing Cash Flow	$-674.0M	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-105.0M	↓ 118.26%
Investing Cash Flow	$201.0M	↓ 0.5%
Financing Cash Flow	$-1.7B	↑ 158.75%

Teva Pharmaceutical Industries Technicals Summary

Sell

Neutral

Buy

Teva Pharmaceutical Industries is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Teva Pharmaceutical Industries Ltd Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Teva Pharmaceutical Industries Ltd	9.5%	7.79%	-2.35%	72.23%	76.13%
Haleon Plc Spon Ads	1.26%	-3.4%	-1.23%	61.37%	30.23%
United Therapeutics Corporation	6.83%	-16.01%	-10.17%	39.52%	76.09%
Zoetis Inc.	4.57%	-1.51%	-16.46%	-9.09%	-2.82%
Neurocrine Biosciences Inc.	0.81%	16.61%	-10.35%	24.21%	17.48%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Teva Pharmaceutical Industries Ltd	30.17	NA	1.29	2.58	-0.02	0.05	NA	5.95
Haleon Plc Spon Ads	21.44	21.44	3.08	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.95	0.19	0.13	NA	158.65
Zoetis Inc.	26.53	26.53	2.49	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	39.32	39.32	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Teva Pharmaceutical Industries Ltd	Sell	$20.5B	76.13%	30.17	-0.94%
Haleon Plc Spon Ads	Buy	$43.6B	30.23%	21.44	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.09%	12.22	40.36%
Zoetis Inc.	Buy	$68.3B	-2.82%	26.53	27.83%
Neurocrine Biosciences Inc.	Buy	$13.2B	17.48%	39.32	13.88%

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Organization	Teva Pharmaceutical Industries
Employees	37000
CEO	Mr. Richard D. Francis
Industry	Health Technology

Key Management of Teva Pharmaceutical Industries Ltd

Name	Title
Mr. Richard D. Francis	President, CEO & Director
Mr. Eliyahu Sharon Kalif	Executive VP & CFO
Mr. Richard Gordon Daniell	Executive Vice President of European Commercial
Dr. Eric A. Hughes M.D., Ph.D.	Executive VP of Global R&D and Chief Medical Officer
Ms. Christine Fox	Executive VP of U.S. Commercial Business
Mr. Matthew Shields	Executive Vice President of Global Operations
Mr. Amir Weiss	Senior VP & Chief Accounting Officer
Mr. Christopher J. Stevo CFA	Senior Vice President of Investor Relations & Competitive Intelligence
Kathleen Veit	Senior Vice President, Global Compliance & Ethics Officer
Mr. David R. Mcavoy J.D.	Executive VP & Chief Legal Officer

Important FAQs about investing in TEVA Stock from India :

What is Teva Pharmaceutical Industries share price today?

Teva Pharmaceutical Industries share price today is $18.21 as on August 19, 2025 at 12:37 AM IST. Teva Pharmaceutical Industries share today touched a day high of $18.26 and a low of $18.01.

What is the 52 week high and 52 week low for Teva Pharmaceutical Industries share?

Teva Pharmaceutical Industries share touched a 52 week high of $22.80 and a 52 week low of $12.47. Teva Pharmaceutical Industries stock price today, August 19, 2025 at 12:37 AM IST is trending at $18.21, lower by 20.13% versus the 52 week high.

How to invest in Teva Pharmaceutical Industries Stock (TEVA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Teva Pharmaceutical Industries on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Teva Pharmaceutical Industries Shares that will get you 0.0824 shares as per Teva Pharmaceutical Industries share price of $18.21 per share as on August 19, 2025 at 12:37 AM IST.

What is the minimum amount required to buy Teva Pharmaceutical Industries Stock (TEVA) from India?

Indian investors can start investing in Teva Pharmaceutical Industries (TEVA) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Teva Pharmaceutical Industries stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Teva Pharmaceutical Industries share’s latest price of $18.21 as on August 19, 2025 at 12:37 AM IST, you will get 0.5491 shares of Teva Pharmaceutical Industries. Learn more about fractional shares .

What are the returns that Teva Pharmaceutical Industries has given to Indian investors in the last 5 years?

Teva Pharmaceutical Industries stock has given 76.13% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?